[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-infarction-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-infarction-acute":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,67,103,137,164,187,209,238,274,295],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100535464","registry-of-acute-myocardial-infarction-100535464",false,"NCT06252168","Registry of Acute Myocardial Infarction","RAMI-Tomsk","Inclusion Criteria:\n\n* age of at least 20 years;\n* being a resident or visitor of the city of Tomsk at a time of AMI onset;\n* the presence of definite AMI or possible AMI. Definite AMI is diagnosed in the presence of characteristic ECG changes, regardless of clinical course and changes in serum enzymes; or the presence of typical pain syndrome, \"ambiguous\" ECG changes, and definite increase in the activity of serum enzymes i.e. exceeding the upper limit of normal by 25% or more; or macroscopically detected focus of myocardial necrosis and (or) fresh thrombotic occlusion of the coronary artery. Possible AMI is registered in the presence of typical pain syndrome with ambiguous ECG changes and an ambiguous (up to 25%) increase in the levels of serum enzymes; or the presence of obstruction in the lumen of at least one coronary artery by at least 50% and (or) the presence of a post-infarction scar in the myocardium with a diameter of 0.5 cm or more, while simultaneously excluding a non-coronary cause of death. In case of atypical clinical picture, ambiguous or absent ECG changes, when the enzyme levels are not determined or their activity does not reach a pathological level, AMI case is considered unconfirmed. In the absence of data that could confirm or not confirm AMI, the case is interpreted as \"insufficient data\"\n\nExclusion Criteria:\n\n* none.","ALL","20 Years",{"count":19,"type":20},97500,"ESTIMATED","OBSERVATIONAL","The Registry of Acute Myocardial Infarction (RAMI) aims at regular and centralized acquiring and processing standard information about verified and suspected cases of acute myocardial infarction (AMI), monitoring of AMI cases, and establishing AMI diagnosis based on standard diagnostic criteria by doctors involved in the registry. The RAMI obtains data from all medical institutions, which could potentially document any cases of suspected AMI.",[24],"Myocardial Infarction, Acute",[26,27],"Acute Myocardial Infarction","Acute Coronary Syndrome","RECRUITING","2026-06-19",{"date":31,"type":32},"2026-06-24","ACTUAL",{"date":34,"type":32},"1984-01-01",{"date":36,"type":20},"2050-12-31",{"name":38,"class":39},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100417693","periodontal-health-in-patients-acutely-admitted-for-myocardial-infarction-a-case-control-study-100417693","NCT04719026","PERIODONTAL HEALTH IN PATIENTS ACUTELY ADMITTED FOR MYOCARDIAL INFARCTION: A CASE CONTROL STUDY","PEDICAD","Inclusion Criteria:\n\n* cases: Patients aged 20-90 admitted with acute myocardial infarction\n* controls: Dental patients, aged 20-90, matched to patients in the case study group for age, gender (±7) and risk factors for coronary artery disease (hypertension, obesity, diabetes, smoking, hypercholesterolaemia) but with no history of myocardial infarction)\n\nExclusion Criteria:\n\n* Severe co-morbidities, Inability to consent, pregnant participants will be excluded, participants with other systemic inflammatory diseases, patients taking antimicrobials or antibiotics in last three years, patients taking medications, such as cyclosporine, calcium channel blockers, phenytoin, immunocompromised patients, patients with malignancies, patinets with type-2 or type-3 hypersensitivities","90 Years",{"count":50,"type":20},320,"Heart attack remains a major cause of death in adult population worldwide and especially within Scotland. A large portion of the general population has an increased risk of suffering from a heart attack because of their genetic make-up, disease profile and lifestyle choices.\n\nLiterature suggests that apart from these known risk factors, long-standing inflammation (reaction of tissues to infection or injury) elsewhere in the body may be responsible for heart attacks. It has been suggested that gum disease may be one such condition. If left untreated, gum disease may expose the entire body to a long-term inflammatory burden where inflammatory molecules can disseminate from the gums into the bloodstream and affect various body structures. This study explores the influence of gum disease on the risk of heart attack by comparing the gum health of participants who recently had a heart attack to the gum health of participants with no history of heart problems after accounting for other risk factors. Findings will provide critical information for the design of our forthcoming study to establish the effect of treatment of gum disease on the risk of heart attack, and its cost-effectiveness. Ultimately this research will tackle another risk factor for heart attacks and thus inform enhancement of public health prevention strategies.",[24,53],"Periodontitis",[55,56,57],"myocardial infarction","coronary artery disease","periodontal diseases","2026-05-04",{"date":60,"type":32},"2026-05-08",{"date":62,"type":32},"2018-02-16",{"date":64,"type":20},"2027-03-14",{"name":66,"class":39},"University of Aberdeen",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":40},"100436864","timing-of-ffr-guided-pci-for-non-ira-in-nstemi-and-mvd-option-nstemi-100436864","NCT04968808","Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)","OPtimal TIming of Fractional Flow Reserve-Guided Complete RevascularizatiON in Non-ST-Segment Elevation Myocardial Infarction (OPTION-NSTEMI)","Inclusion Criteria:\n\n1. Age ≥ 19 years old\n2. Non-ST-segment elevation myocardial infarction\n\n   * Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and,\n\n     * occurs at rest, usually lasting \\> 10 minutes\n     * severe and new onset (within the prior 4-6 weeks)\n     * crescendo pattern\n   * Elevated cardiac biomarkers and,\n\n     * ≥ 99% value of high-sensitivity cardiac troponin\n   * No ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads or newly developed left bundle branch block on 12-lead electrocardiogram\n3. PCI within 72 hours after symptom development\n4. Multivessel disease: Non-IRA with at least 2.5 mm diameter and 50% diameter stenosis by visual estimation\n5. Patient's or protector's agreement about study design and the risk of PCI\n\nExclusion Criteria:\n\n1. Cardiogenic shock at initial presentation or after treatment of IRA\n2. TIMI flow at non-IRA ≤ 2\n3. Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators' decision\n4. Non-IRA lesion not suitable for PCI treatment by operators' decision\n5. Chronic total occlusion at non-IRA\n6. History of anaphylaxis to contrast agent\n7. Pregnancy and lactation\n8. Life expectancy \\\u003C 1-year\n9. Severe valvular disease\n10. History of CABG, or planned CABG\n11. Fibrinolysis before admission","19 Years",{"count":76,"type":20},1014,"INTERVENTIONAL",[79],"NA","Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (percutaneous coronary intervention \\[PCI\\] for both infarct-related artery \\[IRA\\] and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of fractional flow reserve (FFR), and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.",[24,82,83],"Multi-Vessel Coronary Artery Stenosis","Multi Vessel Coronary Artery Disease",[85,86,82,87,88,89,90,91,92,93],"Non-ST-Segment Elevation Myocardial Infarction","Multi-Vessel Coronary Artery Disease","Culprit-Only","Multi-Vessel Percutaneous Coronary Intervention","Percutaneous Coronary Intervention","Complete Revascularization","Timing","Staged Percutaneous Coronary Intervention","Fractional Flow Reserve","2026-04-22",{"date":96,"type":32},"2026-04-27",{"date":98,"type":32},"2021-09-01",{"date":100,"type":20},"2028-08-31",{"name":102,"class":39},"Chonnam National University Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":77,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100454534","phase-2-stratified-medicine-of-eplerenone-in-acute-myocardial-infarction-or-injury-and-no-obstructive-coronary-arteries-100454534","NCT05198791","Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.","The Effect of Mineralocorticoid Receptor Antagonist Therapy in Patients With Acute Myocardial Infection or Injury and no Obstructive Coronary Arteries: a Registry-based, Stratified-medicine, Randomized, Controlled Trial","StratMedMINOCA","Inclusion Criteria:\n\n* Age ≥18 years.\n* Acute myocardial infarction or myocardial injury and no obstructive coronary arteries.\n* Cardiovascular risk factor (≥1): age \\>70 years, atrial fibrillation, diabetes, current smoker, eGFR 30 - 60 mL\u002F minute\u002F1.73 m2, prior MI, treated hypertension or COVID-19 (confirmed or suspected)\n* Coronary angiography.\n\nExclusion Criteria (trial):\n\n* Obstructive coronary artery disease\n* Left ventricular ejection fraction ≤40% with evidence of heart failure, following myocardial infarction.\n* Estimated glomerular filtration rate \\\u003C30 mL\u002F minute\u002F1.73 m2\n* Severe liver impairment\n* Women who are pregnant, breast-feeding or of child-bearing potential (WoCBP) without a negative pregnancy test and who are unwilling or unable to follow the reproductive restrictions defined in the eligibility criteria and use highly effective contraception as defined in Appendix 2 for the duration of the study treatment and 30 days after last dose of study drug.\n* Patients taking one of the following medicines :\n* Pre-existing treatment with an MRA :\n* Anti-fungal drugs (ketoconazole or itraconazole).\n* Antiviral medication (nelfinavir or ritonavir).\n* Antibiotics (clarithromycin or telithromycin).\n* Nefazodone used to treat depression.\n* The combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB)) together.\n\nExclusion Criteria (registry):\n\n* Contra-indication to cardiovascular magnetic resonance imaging e.g. severe claustrophobia, metallic foreign body.\n* Contra-indication to intravenous adenosine, i.e. severe asthma; long QT syndrome; second- or third-degree atrio-ventricular block and sick sinus syndrome.\n* Lack of informed consent.","18 Years",{"count":113,"type":20},400,[115],"PHASE2","Patients with heart attack or heart injury are tested (angiogram) for blockages in their arteries. Patients may develop heart problems caused by damage to small (microvascular) blood vessels. Eplerenone, a mineralocorticoid receptor-selective antagonist, reduces blood vessel injury and is used to treat high blood pressure and heart failure.\n\nAim: to test the use of eplerenone in patients with heart attack\u002Fheart injury an no obstructive coronary arteries and small vessel problems (coronary microvascular dysfunction).\n\nPatients admitted to hospitals in the West of Scotland (2.5 million) and referred for invasive management to the Golden Jubilee and Hairmyres hospitals because of a suspected heart attack heart will be invited to participate into a registry-based clinical trial. Screening, enrolment and verbal, informed consent will be obtained during the angiogram then written consent on the ward. Small vessel disease will be assessed using a 'diagnostic' guidewire during the standard angiogram. People with small vessel problems will be invited to participate in a clinical trial of usual care or eplerenone. Coronary microvascular dysfunction is defined as an index of microvascular resistance ≥25. Coronary flow reserve (CFR abnormal \\\u003C2.0), microvascular resistance reserve ratio (MRR, abnormal \\\u003C2.5), and resistance reserve ratio (RRR abnormal \\\u003C2.0), measured simultaneously with IMR, are predefined parameters of interest.\n\nPatients will be allocated into one of the 3 groups:\n\n* Group 1: Patients without coronary microvascular dysfunction. No eplerenone\n* Group 2: Patient with coronary microvascular dysfunction. Usual care, no eplerenone.\n* Group 3: Small vessels abnormal. Eplerenone tablets.\n\nThe primary outcome for the trial will be reduced heart injury (biomarkers) in patients with microvascular disease. We will also test heart function (MRI scan) at enrolment and at six months. All patients (Groups 1, 2 and 3) will have an angiogram. Standard blood tests will be collected during the hospital stay, and then again at 1 and 6 months. Other outcomes include questionnaires (health status). We will gather information on longer-term health outcomes (hospitalisation, death) using confidential electronic record linkage. We will ask for permission to store blood samples for future research.\n\nThe research will improve scientific knowledge about eplerenone therapy in this patient group. The study will create a repository of clinical samples and images which will provide vital data for studies of endotypes of myocardial infarction or injury with no obstructive coronary arteries.",[24,118,119],"Myocardial Infarction With Nonobstructive Coronary Arteries","Myocardial Injury",[121,122,123,124,125,126],"Stratified Medicine","Mineralocorticoid receptor antagonists","MINOCA","Myocardial injury","Myocardial infarction","Myocardial Infarction with Nonobstructive Coronary Arteries","2026-03-12",{"date":129,"type":32},"2026-03-16",{"date":131,"type":32},"2022-02-04",{"date":133,"type":20},"2026-07-31",{"name":135,"class":39},"NHS National Waiting Times Centre Board",2,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":145,"targetDuration":147,"studyType":21,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":136},"100624423","korea-acute-myocardial-infarction-registry-100624423","NCT07409441","Korea Acute Myocardial Infarction Registry","A Multicentre Observational Study to Improve Long-term Prognosis in Korean Patients With Acute Myocardial Infarction (Korea Acute Myocardial Infarction Registry [KAMIR-7])","KAMIR-7","Inclusion Criteria:\n\n* Age ≥ 19 years\n* Patients diagnosed with acute myocardial infarction (AMI) (either ST-segment elevation myocardial infarction \\[STEMI\\] or non-ST-segment elevation myocardial infarction \\[NSTEMI\\]), meeting both of the following:\n* Elevated cardiac troponin above the 99th percentile upper reference limit\n* Evidence of myocardial ischemia, as indicated by symptoms, electrocardiographic (ECG) changes, and\u002For imaging evidence\n\nExclusion Criteria:\n\n\\- Patients who do not provide informed consent to participate in this study",{"count":146,"type":20},20000,"3 Years","This multicentre observational registry study, the Korea Acute Myocardial Infarction Registry (KAMIR-7), aims to improve long-term prognosis in Korean patients with acute myocardial infarction (AMI) by establishing and operating a nationwide patient registry system. Participating hospitals across Korea, treating AMI patients, will contribute prospective clinical and health-related data. The registry system is web-based and designed to support various clinical and epidemiologic research initiatives, provide standardized data, and facilitate collaborative studies, including participation in international studies such as GRACE.\n\nThe primary objectives are:\n\n1. To establish and maintain a sustainable nationwide AMI patient registry to enable continuous collection of high-quality clinical data.\n2. To develop a Korean-specific AMI prognostic model by evaluating the applicability and discriminative power of existing foreign risk prediction models (e.g., GRACE score, TIMI score, PERSUIT model, ACTION score) using domestic patient data.\n3. To identify clinical and management factors significantly affecting AMI outcomes and model mortality risk using accessible clinical and initial presentation data, including total ischemic time (symptom-to-hospital and door-to-balloon time).\n4. To develop clinical and quality indicators to evaluate appropriateness of care and emergency management systems, incorporating patient transport, pre-hospital management, and hospital treatment timeliness.\n\nSecondary objectives include:\n\n* To ensure sustainable patient enrollment and prospective follow-up systems that can support clinical and public health research.\n* To create a resource for future research on new antiplatelet agents, stents, or interventional strategies.\n* To provide data for nested case-control studies within the cohort, facilitating research on clinical characteristics, treatment courses, and outcomes in AMI patients.\n* To identify new prognostic factors influencing patient outcomes and establish guidelines appropriate for Korean clinical practice.\n* To address limitations of prior KAMIR studies, including short follow-up duration and limited heart failure-related data, and incorporate evolving treatment strategies, devices, and medications.\n\nThrough systematic data collection and networked collaboration, this study will enable comprehensive analyses of long-term outcomes in Korean AMI patients, contribute to evidence-based optimization of treatment strategies, support development of prognostic tools specific to the Korean population, and inform health policy and clinical guideline refinement. The registry will also foster research collaboration among hospitals, investigators, and international study networks to advance the understanding and management of AMI in Korea.",[24],[26,89,151,152,153],"Coronary Angiography","ST-Elevation Myocardial Infarction","Non-ST-Elevation Myocardial Infarction","NOT_YET_RECRUITING","2026-03-09",{"date":157,"type":32},"2026-03-10",{"date":159,"type":20},"2026-03-01",{"date":161,"type":20},"2031-12-31",{"name":163,"class":39},"Samsung Medical Center",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":172,"minAge":111,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":40},"100606881","wamif-prospective-study-in-young-women-presenting-acute-myocardial-infarction-cohort-follow-up-100606881","NCT07181317","WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction: Cohort Follow up","WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction in France: Clinical, Morphological and Biological Descriptive Analysis: Cohort Follow up","WAMIF-suivi","All patients who participated in the WAMIF study (research registration number with the French Ministry of Health : 2015-A01263-46 \u002F Protocol registration with Clinical Trials NCT03073447) and wish to continue follow-up in the study.","FEMALE","60 Years",{"count":175,"type":20},314,"The WAMIF study was conducted from 2017 to 2019, including 314 patients in 30 French research centers spread across metropolitan France. It systematically collected the clinical, morphological, and biological characteristics of myocardial infarction cases affecting women under 50 years of age and assessed their short-term (in-hospital) and medium-term (12-month) prognosis. Extending the follow-up beyond 12 months for this first study would provide fundamental data for understanding and improving the care of these patients.",[24],"2026-01-09",{"date":180,"type":32},"2026-01-12",{"date":182,"type":32},"2025-11-25",{"date":184,"type":20},"2029-09-30",{"name":186,"class":39},"French Cardiology Society",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":207,"locationsCount":40},"100317422","asan-medical-center-myocardial-infarction-registry-100317422","NCT03412435","Asan Medical Center Myocardial Infarction Registry","Asan-MI","Inclusion Criteria:\n\n* All consecutive acute myocardial infarction patients diagnosed through coronary angiography",{"count":195,"type":20},5000,"This study evaluates long-term outcome of patients diagnosed as acute myocardial infarction and treated with medication, coronary artery bypass surgery and percutaneous coronary intervention in Asan medical center, Korea.",[24,198],"Coronary Stenosis",[200,125],"Acute myocardial infarction","2025-12-28",{"date":203,"type":32},"2026-01-02",{"date":205,"type":32},"2018-04-27",{"date":161,"type":20},{"name":208,"class":39},"Seung-Jung Park",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":48,"enrollmentInfo":217,"targetDuration":4,"studyType":77,"phases":219,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100497579","phase-4-effect-of-intravenous-ferric-carboxymaltose-onmortality-and-cardiovascular-morbidity-and-quality-of-life-in-iron-deficient-patients-with-recent-myocardial-infarction-100497579","NCT05759078","Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion","Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion SUBTITLE Prevention of Cardiovascular Death, Heart Failure Events and Deterioration in Quality of Life With INtravenous FERRic Carboxymaltose in Iron Deficient Patients With Recent Myocardial Infarction","INFERRCT","Inclusion criteria:\n\n1. Age ≥18 years;\n2. Diagnosis of AMI (STEMI or NSTEMI) up to 4 weeks (28 days) before randomisation\n3. Presence of iron deficiency (ID) defined as transferrin saturation TSAT\\\u003C20% assessed within up to 4 weeks (28 days) before randomisation;\n4. Presence of ≥3 factors (confirmed within up to 4 weeks before randomisation) (note: at least one of a-c must be present):\n\n   1. LVEF ≤50%;\n   2. NT-proBNP ≥400 pg\u002FmL for subjects in sinus rhythm and NT-proBNP ≥800 pg\u002FmL for subjects with atrial fibrillation;\n   3. Clinical features of congestion\u002Fvolume overload (including Killip class II or more) requiring i.v. loop diuretic use;\n   4. Diagnosis of diabetes mellitus (also de novo diagnosis);\n   5. Diagnosis of atrial fibrillation (any time in the past or de-novo diagnosis);\n   6. Multivessel coronary disease (regardless of completeness of revascularisation during an index AMI);\n   7. Not complete revascularisation or\u002Fand no reperfusion (during an index AMI);\n   8. History of AMI (despite an index AMI);\n   9. eGFR \\\u003C60 mL\u002Fmin\u002F1.73m2; 1. Age ≥70 years.\n5. Written informed consent\n\nExclusion criteria:\n\n1. Subject temperature \\>38 ͦ C or any infection requiring antibiotic therapy within 48 hours prior to randomisation;\n2. Severe, symptomatic valve disorder;\n3. Urgent hospitalisation for whatever reasons (percutaneous\u002Fsurgical procedure requiring hospitalisation within 4 weeks prior to randomisation).\n4. Body weight \\\u003C50 kg;\n5. Haemoglobin \\\u003C8 g\u002FdL or \\>15,5 g\u002FdL;\n6. Serum ferritin \\>400 ng\u002FmL;\n7. Active gastroenteral bleeding;\n8. Known hypersensitivity to any of the administered preparations;\n9. Treatment with erythropoiesis stimulating factors, i.v. iron therapy or blood transfusion within 6 months prior to randomisation;\n10. Subject has known active malignancy of any organ system, i.e., clinical evidence of current malignancy or not in stable remission for at least 3 years since completion of last treatment with exception of non-invasive basal cell carcinoma, squamous cell carcinoma of the skin or cervical intra-epithelial neoplasia;\n11. Documented liver diseases;\n12. Participation in a device or drug trial within 3 months prior to randomisation or 5 half-lives, whichever period is longer, prior to the screening visit;\n13. Pregnancy or lactation;\n14. Any situation that may prevent the test from being performed in accordance with the protocol, or the consent of the investigator to be given in writing, including alcohol, drugs or any other substance overuse or addiction.",{"count":218,"type":20},1000,[220],"PHASE4","Non-commercial, multicentre, randomised, double-blind, parallel group, placebo-controlled clinical trial. Eligible patients were randomly assigned (1:1) using a secure, central, interactive, web-based response system, to intervention FCM or placebo arm. Time of observation: minimum of 8 months up to a maximum of 36 months.\n\nPrimary Study Objective: Primary:\n\nEvaluation of the effect of i.v. FCM treatment compared with placebo on the risk of death, the risk of heart failure events (HFE\\*) (number of events and time to first event), NTproBNP concentration and the change in quality of life (QoL) assessed using EQ-5D during the follow-up up to 36-months in patients with recent AMI and ID (with an implementation of a win ratio approach in a hierarchical descending order).\n\n\\*HFE: unplanned hospitalization for HF (including unplanned visit at emergency department due to HF), ambulatory significant intensification of diuretic therapy (either starting i.v. loop diuretic or more than doubling oral loop diuretic dose or de novo initiation of oral loop diuretic therapy due to HF signs\u002Fsymptoms).",[24],[125,224,225,226,227],"acute","iron deficiency","Infusion","ferric carboxymaltose","2025-07-25",{"date":230,"type":32},"2025-07-30",{"date":232,"type":32},"2022-09-22",{"date":234,"type":20},"2026-12-31",{"name":236,"class":39},"Wroclaw Medical University",43,{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":246,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":77,"phases":249,"briefSummary":250,"conditions":251,"keywords":259,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":40},"100593588","high-sensitivity-troponin-i-in-addition-to-guideline-based-care-in-ems-100593588","NCT07008391","High-Sensitivity Troponin I in Addition to Guideline-Based Care in EMS","High-Sensitivity Troponin I in Addition to Guideline-Based Care in Emergency Medical Service - an Open Randomized Controlled Trial","TIGER","Inclusion Criteria:\n\n* Chestpain \u002F discomfort and\u002For\n* Clinical suspicion of myocardial infarction by the prehospital personeel\n\nExclusion Criteria:\n\n* Patients suffering from a trauma and conveyed to the trauma level 1 hospital.\n* Missing valid social security number\n* Not beeing able to give informed consent\n* Not a primary assignment",true,{"count":248,"type":20},1419,[79],"The TIGER study is a study investigating the utlility of a point-of-care blood analyse of Troponin I to help identify patients with heart attacks in the prehospital emergency care. The study is conducted within the ambulance services of Region Stockholm and compares standard medical care with and without the addition of this quick test.\n\nChest pain is one of the most common reasons for ambulance dispatch, but currently only about one-third of heart attacks are detected before arriving at the hospital-mainly through ECG. The remaining two-thirds are not identified until after further testing at the emergency department. The TIGER study aims to improve early diagnosis by using a high-sensitivity, point-of-care Troponin I test already in the prehospital phase.\n\nThe study is a randomized controlled trial, where participants are randomly assigned to one of two groups. One group receives standard emergency care along with the rapid Troponin I test in the ambulance. The other group receives standard care without the test. The goal is to evaluate whether the use of Troponin I testing leads to faster and more accurate identification of heart attacks, ultimately improving patient outcomes.\n\nIn total, about 1,419 adult patients with chest pain or suspected heart attack will participate. The primary outcome being measured is the time from first medical contact to PCI (balloon angioplasty). Secondary outcomes include time spent in different parts of care, hospital length of stay, the occurrence of serious events (such as heart attack, stroke, or death), and the diagnostic accuracy of the test.\n\nThe study has been approved by the Swedish Ethical Review Authority and includes safety monitoring through an interim analysis after the first 150 patients. Test results from the Troponin I analysis are clearly marked as part of the research study and should be interpreted by the responsible physician alongside other clinical findings.",[252,253,254,255,256,24,257,258],"Emergency Medical Services","Nursing Care","Cardiology","Myocardial Infarction","Myocardial Infarction or Chest Pain","Emergencies","Ambulance",[258,260,261,262,263,264],"Prehospital emergency nurse","Sweden","Point-of-care","troponin","high sensitive troponin","2025-06-27",{"date":267,"type":32},"2025-07-02",{"date":269,"type":32},"2025-06-25",{"date":271,"type":20},"2026-12-30",{"name":273,"class":39},"Karolinska Institutet",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":281,"maxAge":173,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":40},"100569753","understanding-novel-variants-in-acute-myocardial-infarction-in-young-adults-100569753","NCT06698341","UNdeRstAnding Novel Variants in AcutE MyocardiaL Infarction in Young Adults","UNRAVEL","Inclusion Criteria:\n\n1. Adult \\>21 years old.\n2. Age ≤50 years old irrespective of the presence of CV risk factors\\* at the time of myocardial infarction OR Age 51-60 years old with no more than 2 CV risk factor\\* at the time of myocardial infarction, excluding diabetes mellitus\n3. Able to provide informed consent.\n4. Patients who are willing and able to comply with the study visit and procedures.\n5. Prior type 1 myocardial infarction with angiographically\u002FCT documented significant stenosis of ≥50% in LM or ≥70% in major epicardial\u002Fbranch vessel (e.g. LAD, LCX, RCA).\n6. Patients who are from the three main races (Chinese, Malay, Indian). Race is self-identified by patient.\n\n   * Hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoker\n\nExclusion Criteria:\n\n1. Known familial hypercholesterolaemia, known vasculitides, end-stage renal disease and congenital heart disease.\n2. Prior PAD and Stroke\n3. Female patients who are pregnant\n4. Patients who are non-Asian","21 Years",{"count":283,"type":20},1200,"Cardiovascular disease (CVD) imposes significant mortality and morbidity worldwide. However, large gaps in our knowledge of CVD still exist. The clinical conundrum of the extremes of spectrums of CVD continues to baffle clinicians and researchers alike. These include patients without any major cardiovascular (CV) risk factors developing acute myocardial infarction (AMI) at a relatively young age (\\\u003C50-60 years old), while at the other end of the spectrum, there are also patients with multiple CV risk factors but with minor or no coronary artery disease. These suggest the presence of other factors that predispose these patients to AMI.Recent advancements in technology, especially in the field of genomics, metabolomics, and proteomics, have led to exciting developments in our understanding of the development and prevention of CVD and AMI. In this study, the investigators aim to identify novel gene variants associated with the onset of MI in relatively young patients with minimal standard CV risk factors such as diabetes, obesity, hypertension and hypercholesterolaemia.Through genomic, metabolomics and proteomics analyses, this may better improve our understanding of the development of CVD and AMI, potentially developing novel preventive measures to reduce the risk or delay the onset as well as tailoring management plans to improve treatment outcomes and reduce adverse events for the patients.",[24],"2024-11-18",{"date":288,"type":32},"2024-11-21",{"date":290,"type":32},"2024-04-29",{"date":292,"type":20},"2028-04",{"name":294,"class":39},"National Heart Centre Singapore",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":77,"phases":307,"briefSummary":308,"conditions":309,"keywords":313,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":40},"100389173","phase-4-assessment-of-the-effects-of-long-term-lipid-lowering-therapy-in-patients-with-primary-stemi-or-nstemi-100389173","NCT04347434","Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI","Assessment of the Effects of Long-term Lipid-lowering Therapy on Parameters of Electrical Myocardial Heterogeneity, Myocardial Deformation Characteristics, Vascular Rigidity, and Quality of Life in Patients With Primary STEMI or NSTEMI","CONTRAST-2","Inclusion Criteria:\n\n1\\. Signed Informed Consent Form 2 Primary STEMI or NSTEMI confirmed by ECG, troponin I and CPK-MB levels, coronary angiography.\n\n3\\. Presence of an infarct-related artery according to coronary angiography.\n\nExclusion Criteria:\n\n1. Presence of hemodynamically relevant stenosis exceeding 30% in several coronary arteries confirmed by CAG;\n2. Recurrent or repeated myocardial infarction.\n3. Exogenous hypertriglyceridemia (type 1 hyperchilomicronemia).\n4. The development of acute heart failure III-IV prior to randomization\n5. Individual intolerance to statins, ezetimibe.\n6. Congenital and acquired heart diseases.\n7. Severe concomitant diseases in the stage of decompensation.\n8. Non-sinus rhythm, established artificial pacemaker.\n9. Sinoatrial and atrioventricular blockade of 2-3 degrees.\n10. QRS complex exceeding 100 ms.\n11. The presence of severe LV hypertrophy according to echocardiography.\n12. Uncontrolled hypertension with SBP\\> 180 mm Hg and DBP\\> 110 mmHg\n13. Diabetes mellitus (DM) type 1 and 2.\n14. Current existence of severe anemia (Hb \\\u003C 100 g\u002FL)\n15. Chronic kidney disease (creatinine clearance less than 30 ml \u002F min \u002F 1.73 m2 according to the CKD-EPI).\n16. Non-corrected thyroid dysfunction with hyper \u002F hypothyroidism.\n17. Body mass index (BMI) ≥35 kg \u002F m2.\n18. Pregnancy, lactation.\n19. Alcohol abuse, drug addiction.\n20. Other serious concomitant diseases that exclude the possibility of study participation.\n21. Participation in other clinical trials within the last two months.","30 Years","70 Years",{"count":306,"type":20},300,[220],"In a single-center, open-label, prospective, controlled, clinical study, it is planned to include 300 patients hospitalized in the cardiology department of SBHI Penza regional clinical hospital n.a. N.N. Burdenko. Recruitment of patients will be carried out at the Department of Therapy of the Medical Institute of the Penza State University. Patients meeting the inclusion criteria and not meeting the exclusion criteria will be included in the study.\n\nInitially, lipid-lowering treatment with atorvastatin is prescribed at a dose of 80 mg \u002F day from the first 24-96 hours of AMI in addition to the standard therapy.\n\nIf there is no achievement of the target level of LDL-C, ≤1.5 mmol \u002F L after 5-6 weeks from the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time \u002F day.\n\nStandard AMI treatment includes dual antiplatelet therapy, ACE inhibitors, beta-blockers (if indicated). Prescription of proton pump inhibitors and nitrates is possible (if indicated).\n\nThe total follow-up is 96 weeks. Prescreening - 600 people; screening and randomization - 300 people. Parameters of electrical myocardial heterogeneity, myocardial deformation characteristics, vascular rigidity, and quality of life will be assessed according to the study plan.",[24,310,311,312],"Myocardial Strain","Arterial Stiffness","Quality of Life",[314,315,316,317,318,319],"STEMI","NSTEMI","myocardial strain,","arterial stiffness,","lipid-lowering therapy,","electrical myocardial heterogeneity","2023-11-22",{"date":322,"type":32},"2023-11-24",{"date":324,"type":32},"2020-02-12",{"date":326,"type":20},"2027-12-30",{"name":328,"class":39},"Penza State University"]